Cargando…
Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance
Pyrazinamide (PZA) is one of the main FDA approved drugs to be used as the first line of defense against Mycobacterium Tuberculosis (MTB). It is activated into pyrazinoic acid (POA) via MTB's pncA gene-encoded pyrazinamidase (PZase). Mutations are most commonly responsible for PZA-resistance in...
Autores principales: | Mehmood, Aamir, Khan, Muhammad Tahir, Kaushik, Aman Chandra, Khan, Anwar Sheed, Irfan, Muhammad, Wei, Dong-Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6914729/ https://www.ncbi.nlm.nih.gov/pubmed/31921809 http://dx.doi.org/10.3389/fbioe.2019.00404 |
Ejemplares similares
-
Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan
por: khan, Muhammad Tahir, et al.
Publicado: (2019) -
Pyrazinamide resistance of novel mutations in pncA and their dynamic behavior
por: Ali, Arif, et al.
Publicado: (2020) -
Gibbs Free Energy Calculation of Mutation in PncA and RpsA Associated With Pyrazinamide Resistance
por: Khan, Muhammad Tahir, et al.
Publicado: (2020) -
Structure guided prediction of Pyrazinamide resistance mutations in pncA
por: Karmakar, Malancha, et al.
Publicado: (2020) -
Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.
por: Lee, K. W., et al.
Publicado: (2001)